Merial and Newport Laboratories have announced a Toll Manufacturing and Distribution Agreement, whereby Newport will toll manufacture and distribute Merial’s autogenous porcine circovirus type 2 (PCV-2) swine vaccines through Newport’s veterinarian and swine integrator customer base.
These vaccines compliment Newport Laboratories’ CircoSpanSM array of solution-based diagnostics, technical support, strain specific production, pinpoint formulations, and customer focused co-factor disease control consultation.
“We see this relationship as a perfect match for the swine business units of each company,” said Steve Parker, director of Swine Marketing, Merial US Region. “Merial will contribute product technical support through a working relationship with Newport Labs. Newport will contribute its sales and marketing capability, including strong relationships with top swine veterinarians, swine producers and key influence leaders.”
Dr. Randy Simonson, COO, Newport Laboratories commented, “The relationship leverages both companies’ strengths. The use of Merial products and technology, along with the support of our strong sales and technical field force, will enhance the profitability of US pork producers through solution-based animal health care offerings.”
Newport and Merial currently collaborate on SwiVax®-MH and Derma-Vac® NF Transdermal Needle-free Vaccination System.